Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy

Journal of Clinical Immunology

Volumn 31, Issue 6, 2011, Pages 1079-1083

  Cameron, Barbara Anne ^a   Emerson, Carol R ^b,c,f   Workman, Cassy ^d   Kelly, Mark D ^e   Lloyd, Andrew R ^a   Post, Jeffrey J ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d AIDS Research Initiative   (Australia)

^e Brisbane Sexual Health and HIV Service   (Australia)

^f ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Coinfection; HCV; Hepatitis; HIV; T cells

Indexed keywords

ALBUMIN; ALPHA INTERFERON; CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; EMTRICITABINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS C ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 8; LOPINAVIR; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RITONAVIR; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME INDUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOREGULATION; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELLS, CULTURED; COINFECTION; ENZYME-LINKED IMMUNOSPOT ASSAY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LIVER; MALE; MIDDLE AGED;

EID: 84856872164     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9587-6     Document Type: Article

References (15)

1. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. JAIDS. 2003;32:259-67. (Pubitemid 36331697)
2. Lo Re V, Kostman JR, Amorosa VK. Management complexities of HIV/HCV coinfection in the 21st century. Clin Liver Dis. 2008;12:587-609. (Pubitemid 351952469)
3. Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut. 2010;59:1252-8.
4. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis. 2002;186:1498-502. (Pubitemid 35286121)
5. Monforte Ade A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. JAIDS. 2001;28:114-23. (Pubitemid 32971058)
6. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS. 2003;17:2191-9. (Pubitemid 37338892)
7. Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. Comparison of qualitative (COBAS AMPLI-COR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol. 2005;43:2590-7. (Pubitemid 40827925)
8. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008;46:3880-91.
9. Cameron B, Bharadwaj M, Burrows J, Fazou C, Wakefield D, Hickie I, et al. Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis. 2006;193:664-71. (Pubitemid 43271499)
10. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary HCV infection. Cell Mol Life Sci. 2009;66:733-56.
11. Rea T, Russo J, Katon W, Ashley R, Buchwald D. Prospective study of the natural history of infectious mononucleosis caused by EBV. J Am Board Fam Pract. 2001;14:234-42.
12. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol. 2001;75:11392-400. (Pubitemid 33063230)
13. Yunihastuti E, Lee S, Gani RA, Saraswati H, Sundaru H, Lesmana L, et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clin Immunol. 2011;139:32-9.
14. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38:S80-9. (Pubitemid 38328169)
15. Rallón NI, Soriano V, Restrepo C, García-Samaniego J, Labarga P, López M, et al. HCV-specific T cell Responses in HIV/HCV coinfected patients on HAART are comparable to those observed in HCV-monoinfected individuals. JAIDS. 2011;57:1-8.